Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
95.72
+1.06 (1.13%)
At close: Apr 27, 2026, 4:00 PM EDT
95.03
-0.69 (-0.72%)
After-hours: Apr 27, 2026, 4:11 PM EDT
Incyte Market Cap
Incyte has a market cap or net worth of $19.04 billion as of April 27, 2026. Its market cap has increased by 67.18% in one year.
Market Cap
19.04B
Enterprise Value
15.52B
1-Year Change
67.18%
Ranking
Category
Stock Price
$95.72
Market Cap Chart
Since December 1, 1998, Incyte's market cap has increased from $887.90M to $19.04B, an increase of 2,044.80%. That is a compound annual growth rate of 11.83%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 24, 2026 | 18.84B | -2.86% |
| Dec 31, 2025 | 19.39B | 45.73% |
| Dec 31, 2024 | 13.31B | -5.44% |
| Dec 29, 2023 | 14.07B | -21.25% |
| Dec 30, 2022 | 17.87B | 10.21% |
| Dec 31, 2021 | 16.21B | -14.88% |
| Dec 31, 2020 | 19.05B | 1.27% |
| Dec 31, 2019 | 18.81B | 38.99% |
| Dec 31, 2018 | 13.53B | -32.29% |
| Dec 29, 2017 | 19.99B | 5.81% |
| Dec 30, 2016 | 18.89B | -6.36% |
| Dec 31, 2015 | 20.17B | 63.32% |
| Dec 31, 2014 | 12.35B | 51.41% |
| Dec 31, 2013 | 8.16B | 274.30% |
| Dec 31, 2012 | 2.18B | 14.96% |
| Dec 30, 2011 | 1.90B | -7.01% |
| Dec 31, 2010 | 2.04B | 88.80% |
| Dec 31, 2009 | 1.08B | 193.21% |
| Dec 31, 2008 | 368.30M | -56.50% |
| Dec 31, 2007 | 846.70M | 72.90% |
| Dec 29, 2006 | 489.70M | 9.92% |
| Dec 30, 2005 | 445.50M | -39.62% |
| Dec 31, 2004 | 737.80M | 48.87% |
| Dec 31, 2003 | 495.60M | 59.97% |
| Dec 31, 2002 | 309.80M | -76.00% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Royalty Pharma | 29.27B |
| Insmed | 29.18B |
| Revolution Medicines | 28.46B |
| BioNTech SE | 26.67B |
| Moderna | 20.12B |
| Roivant Sciences | 19.62B |
| Summit Therapeutics | 17.14B |
| Genmab | 16.46B |